我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

左西孟旦治疗心衰的临床研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
739-741745
栏目:
综述
出版日期:
2013-11-25

文章信息/Info

Title:
Progress in clinical research on levosimendan in treatment of heart failure
作者:
余星燕1综述; 邢 坤2审校
(1.延安大学医学院，陕西 延安 716000；2.陕西省人民医院老年心血管内科，陕西 西安 710068)
Author(s):
YU Xing yan1;  XING Kun2
(1.Medical College of Yan'an University, Yan’an 716000, Shaanxi, China; 2.Department of Older Cardiovascular, People’s Hospital of Shaanxi Province, Xi’an 710068, Shaanxi, China)
关键词:
左西孟旦; 正性肌力药物; 钙离子增敏剂; 心力衰竭
Keywords:
levosimendan;  positive inotropic agent;  calcium sensitiser agent;  heart failure
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
左西孟旦(levosimendan，LS)是一种新型钙增敏剂，其正性肌力作用主要通过增加心肌肌钙蛋白对Ca2+的敏感性和开放细胞膜上ATP敏感的K+通道，增加心肌收缩力，同时扩张外周血管和冠状动脉，减轻心脏前后负荷。LS目前主要用于治疗急性和顽固性心力衰竭（HF）。国内外指南已将其列为IIa类（B级证据），为HF的药物治疗增加了选择。
Abstract:
Levosimendan, a new calcium sensitizer agent, increases myocardial contractility and peripheral and coronary blood vessel vasodilation and reduces preload and afterload via increasing calcium sensitization of cardiac troponin and opening ATPsensitive potassium channels on cell membranes. Levosimendan is currently used mainly in the treatment of decompensated heart failure (HF). The guidelines both at home and abroad have classified it as Class IIa (level of evidence B) for treatment of acute HF in drug selection.

参考文献/References

[1]张 磊,姜 红,邹云增.蛋白质组学在心力衰竭研究中的应用进展[J].中国分子心脏病学杂志,2010,11(3):189-192.
[2]Ribeiro RA,Rohde LE,Polanczyk CA.Levosimendan in acute decompensated heart failure: systematic review and metaanalysis[J].Arq Bras Cardiol,2010,95(2):230-237.
[3]张明惠，杜新平，李玉芬.左西孟旦在难治性心力衰竭中的应用[J].山东医药,2012,52(1):76-77.
[4]王云飞，刘仁光，姜凤伟.左西孟旦治疗重度失代偿心力衰竭的临床观察[J].中国药房,2011,22(30):2856-2858.
[5]Prijic S,Rakic S,Nikolic L,et al.Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children[J].Vojnosanit Pregl,2011,68(11):979-984.
[6]王颖翠，宋 军，牟春霞.左西孟旦对急性心肌梗死伴左室功能不全患者的疗效观察[J].中国社区医师, 2012,14(312):29-30.
[7]陈庆良.左西孟旦乌司他丁与其联合用药对幼兔离体心脏的保护作用[J].中华胸心血管外科杂志,2011,27(4):228-231.
[8]Moiseyev VS,P?der P,Andrejevs N,et al.RUSSLAN Study Investigators.Safety and efficacy of a novel calcium sensitizer levosimendan, in patients with left ventricular failure due to an acute myocardial infarction.A randomized,placebo controlled, doubleblind study(RUSSLAN)[J].Eur Heart J,2002,23(18):1422-1432.
[9]王显悦,毕生辉,王晓武.左西孟旦治疗心脏术后左心室收缩功能低下[J].现代生物医学进展,2012,12(23):4464-4466.
[10]RafouliStergiou P,Parissis JT,AnastasiouNana M.Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?[J].Expert Opin Pharmacother,2012,13(18):2637-2647.
[11]Hou ZQ,Sun ZX,Su CY,et al.Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction[J].Cardiovasc Ther,2013,31(2):108-114.
[12]Zorlu A,Yücel H,Yontar OC,et al.Effect of levosimendan in patients with severe systolic heart failure and worsening renal function[J].Arq Bras Cardiol,2012,98(6):537-843.
[13]杨水祥,魏晓菲.心肾综合征最新研究进展[J].中华临床医师杂志,2010,4(6):789-792.
[14]吴光哲,王 岩,贾建华,等.心肾综合征的临床挑战[J].心血管病学进展,2011,32(3):382-385.

备注/Memo

备注/Memo:
收稿日期：2013-04-10.通讯作者：邢坤，主任医师，主要从事心力衰竭研究 Email：xingkun333@sohu.com 作者简介：余星燕，主治医师，硕士生 Email：sz_shirly@163.com
更新日期/Last Update: 2013-11-20